glp-1 ghrelin Is a glucagon‐like peptide‐1 secretagogue? - Ueno - 2016 - Journal of Diabetes Investigation 1205_s6_article_01

100 million live cultures per serving at time of manufacture

Additionally, we considered articles from the reference lists of relevant studies and literature known to be pertinent by the authors

The key is to have a plan for how to handle it

New medicines that mimic a natural gut hormone called GLP-1 have already changed how clinicians treat type 2 diabetes, obesity and related cardiometabolic consequences

Comparison of direct boiling method with commercial kits for extracting fecal microbiome Dna by Illumina sequencing of 16S rrna tags

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status